Press Releases

2026-10-28 11:02 Firms in Asia Pacific Embrace Unified Workday Platforms
2026-10-28 10:59 Former Nokia Technologies C-suite Executive Joins Sisvel to Lead Creation of New Ventures Unit
2026-10-28 10:16 MUFG Investor Services Appoints McAllister Kirschner Chief Executive Officer
2026-10-28 10:14 NTT DATA Expands AI Factory Footprint Globally to Help Clients Scale AI from Pilots to Production
2026-10-28 10:08 Robbyant’s Inaugural Embodied AI Challenge Draws Over 1,800 Teams Ahead of Real-Robot Final in Shanghai
2026-10-28 10:06 Ant Group Upgrades LingGuang to 2.0, Turning Its AI Assistant into a Proactive Personal Agent
2026-10-28 10:04 SES and CANAL+ Strengthen Strategic Partnership Through 2040
2026-10-27 14:39 Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function
2026-10-27 14:11 SHOJO MANGA INFINITY: Moto Hagio, Ryoko Yamagishi and Waki Yamato - A Major Exhibition Tracing the Expanding Possibilities of Shojo Manga
2026-10-27 14:07 Agent Assurance by TestMu AI Is Now Generally Available, Letting Teams Test What Their AI Agents Actually Change
2026-10-27 11:14 OptionMetrics Exhibiting at Asia EQD
2026-10-27 10:58 Dubai Chambers Launches World's First Agentic AI Marketplace by a Chamber of Commerce
2026-10-27 10:54 Media Release: Allianz Beach Arena for the LA28 Olympic and Paralympic Games Joins the Allianz Family of Stadiums
2026-10-27 10:50 TVS Motor Company Returns to EICMA With New Models for Europe
2026-10-27 10:49 Dubai Culture Opens Registration for ISEA2026 Dubai
2026-10-27 10:27 WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN
2026-10-27 10:10 Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function
2026-10-27 08:26 Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
2026-10-27 08:17 Chidamide Plus Nivolumab Shows Potential as New Standard of Care in Advanced Melanoma, Reducing Disease Progression Risk by 27% in Global Phase 3 Trial
2026-10-26 15:32 BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026